

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 950)

FURTHER ANNOUNCEMENT IN RELATION TO CONNECTED TRANSACTION PROVISION OF FINANCIAL ASSISTANCE

Reference is made to the announcement of Lee's Pharmaceutical Holdings Limited (the "**Company**") dated 25 April 2017 in relations to the provision of financial assistance (the "**Announcement**"). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board would like to provide the following additional information in respect of the Shareholder Loan for the reference of the Shareholders and investors:

- (1) China Oncology Focus Limited ("**COF**") is a company with limited liability and incorporated under the laws of the British Virgin Islands on 20 October 2000 and held by the Company (through Lee's International) as to 65% as at the date of the Announcement.
- (2) COF is treated as an indirect non-wholly owned subsidiary of the Company and is the development arm of oncology products of the Group. The intended use of the Shareholder Loan by COF will be the general working capital for the development of new drugs in oncology therapeutic area and the provision of financial assistance will generate additional profit attributable to the Shareholders. As such, the Directors (including the independent non-executive Directors) are of the view that the provision of the financial assistance given by Lee's International for the benefit of COF will in turn benefit the Group.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 26 April 2017

** For identification purpose only*

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Dr. Marco Maria Brughera is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.